Exact Sciences Corporation (NASDAQ:EXAS) Shares Purchased by Vontobel Holding Ltd.

Vontobel Holding Ltd. lifted its stake in shares of Exact Sciences Corporation (NASDAQ:EXAS - Free Report) by 544.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 37,562 shares of the medical research company's stock after acquiring an additional 31,729 shares during the quarter. Vontobel Holding Ltd.'s holdings in Exact Sciences were worth $1,626,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Exact Sciences in the first quarter valued at approximately $34,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Exact Sciences in the 4th quarter valued at $45,000. AlphaQuest LLC lifted its position in shares of Exact Sciences by 22,825.0% during the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock worth $52,000 after purchasing an additional 913 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in shares of Exact Sciences during the fourth quarter worth $66,000. Finally, Ostrum Asset Management increased its holdings in Exact Sciences by 28.4% in the fourth quarter. Ostrum Asset Management now owns 2,382 shares of the medical research company's stock valued at $134,000 after buying an additional 527 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company's stock.

Exact Sciences Price Performance

EXAS traded down $1.05 on Friday, hitting $52.82. 1,668,708 shares of the company were exchanged, compared to its average volume of 2,579,990. Exact Sciences Corporation has a fifty-two week low of $39.97 and a fifty-two week high of $72.83. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.38 and a current ratio of 2.73. The firm has a market capitalization of $9.96 billion, a P/E ratio of -9.59, a price-to-earnings-growth ratio of 11.39 and a beta of 0.95. The business's fifty day moving average is $53.73 and its 200 day moving average is $51.23.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.16. Exact Sciences had a negative return on equity of 3.75% and a negative net margin of 36.06%. The company had revenue of $706.79 million for the quarter, compared to the consensus estimate of $688.58 million. During the same period in the previous year, the business earned ($0.60) earnings per share. Exact Sciences's quarterly revenue was up 10.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Exact Sciences Corporation will post -0.58 EPS for the current year.

Wall Street Analyst Weigh In

EXAS has been the subject of several analyst reports. Guggenheim reaffirmed a "buy" rating and set a $60.00 price objective on shares of Exact Sciences in a research report on Friday, April 11th. Royal Bank Of Canada raised their price objective on shares of Exact Sciences from $52.00 to $54.00 and gave the stock a "sector perform" rating in a report on Friday, May 2nd. Mizuho started coverage on shares of Exact Sciences in a research note on Thursday, April 10th. They set an "outperform" rating and a $60.00 price target on the stock. Barclays dropped their price objective on Exact Sciences from $75.00 to $65.00 and set an "overweight" rating on the stock in a report on Tuesday, June 24th. Finally, Robert W. Baird boosted their target price on Exact Sciences from $69.00 to $72.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Two analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $70.40.

Insider Activity

In other Exact Sciences news, Director Katherine S. Zanotti sold 3,207 shares of the firm's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $53.20, for a total transaction of $170,612.40. Following the completion of the transaction, the director owned 72,759 shares of the company's stock, valued at approximately $3,870,778.80. This trade represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 1.20% of the stock is owned by corporate insiders.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.